ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.

Background: The ExtaviJect® 30G autoinjector was developed to facilitate parenteral self-administration of interferon beta-1b (Extavia®), a first-line disease-modifying therapy in patients with multiple sclerosis. Our aim was to assess patient compliance with treatment when using the autoinjector, patients' and nurses' experiences of using the device, its tolerability, and patient satisfaction.

Methods: This was a 12-week, real-world, prospective, observational, noninterventional study conducted in nine European countries.

[Biomechanical stress in glaucoma--cause and effect].

Unlabelled: Glaucoma is a neurodegenerative disease with multifactor causes which is characterized by acute loss of ganglion cells. Many mechanisms are involved in this disease but they are incomplete elucidated. Biomechanical stress generate changes to lamina cribrosa which determine ganglion cells death.